209 related articles for article (PubMed ID: 9867151)
41. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and toxicity of 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with human Burkitt's lymphoma (Raji).
DeNardo GL; Kukis DL; Shen S; Mausner LF; Meares CF; Srivastava SC; Miers LA; DeNardo SJ
Clin Cancer Res; 1997 Jan; 3(1):71-9. PubMed ID: 9815540
[TBL] [Abstract][Full Text] [Related]
43. Radiosynthesis of new [90Y]-DOTA-based maleimide reagents suitable for the prelabeling of thiol-bearing L-oligonucleotides and peptides.
Schlesinger J; Fischer C; Koezle I; Vonhoff S; Klussmann S; Bergmann R; Pietzsch HJ; Steinbach J
Bioconjug Chem; 2009 Jul; 20(7):1340-8. PubMed ID: 19552458
[TBL] [Abstract][Full Text] [Related]
44. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.
Shen S; Forero A; LoBuglio AF; Breitz H; Khazaeli MB; Fisher DR; Wang W; Meredith RF
J Nucl Med; 2005 Apr; 46(4):642-51. PubMed ID: 15809487
[TBL] [Abstract][Full Text] [Related]
45. Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study.
Denardo GL; Denardo SJ; Kukis DL; O'Donnell RT; Shen S; Goldstein DS; Kroger LA; Salako Q; Denardo DA; Mirick GR; Mausner LF; Srivastava SC; Meares CF
Anticancer Res; 1998; 18(4B):2779-88. PubMed ID: 9713461
[TBL] [Abstract][Full Text] [Related]
46. Ascorbic acid: useful as a buffer agent and radiolytic stabilizer for metalloradiopharmaceuticals.
Liu S; Ellars CE; Edwards DS
Bioconjug Chem; 2003; 14(5):1052-6. PubMed ID: 13129412
[TBL] [Abstract][Full Text] [Related]
47. A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma.
O'Donnell RT; DeNardo GL; Kukis DL; Lamborn KR; Shen S; Yuan A; Goldstein DS; Carr CE; Mirick GR; DeNardo SJ
J Nucl Med; 1999 Dec; 40(12):2014-20. PubMed ID: 10616879
[TBL] [Abstract][Full Text] [Related]
48.
Scotognella T; Maccora D; Bruno I; Chinol M; Castagnola M; Collamati F; Mancini-Terraciano C; Morganti S; Bocci V; Camillocci ES; Rotili D; Cartoni A; Fratoddi I; Marini F; Venditti I; Faccini R; Giordano A
Curr Radiopharm; 2022; 15(1):32-39. PubMed ID: 33397277
[TBL] [Abstract][Full Text] [Related]
49. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
50. Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates.
Kukis DL; DeNardo GL; DeNardo SJ; Mirick GR; Miers LA; Greiner DP; Meares CF
Cancer Res; 1995 Feb; 55(4):878-84. PubMed ID: 7850803
[TBL] [Abstract][Full Text] [Related]
51. Intralesional radioimmunotherapy with Yttrium-90-labeled human monoclonal IgM in nude mice bearing human tumor xenografts.
Borchardt PE; Vriesendorp HM; Freedman RS; Quadri SM
Cancer Biother Radiopharm; 2004 Feb; 19(1):43-51. PubMed ID: 15068610
[TBL] [Abstract][Full Text] [Related]
52. Stability of monoclonal antibodies, Lym-1 and ChL6, and 2IT-BAD-Lym-1 immunoconjugate with ultra freezer storage.
Kukis DL; DeNardo SJ; Mills SL; Shen S; O'Donnell RT; DeNardo GL
Cancer Biother Radiopharm; 1999 Oct; 14(5):363-9. PubMed ID: 10850321
[TBL] [Abstract][Full Text] [Related]
53. 67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma.
O'Donnell RT; DeNardo GL; Kukis DL; Lamborn KR; Shen S; Yuan A; Goldstein DS; Mirick GR; DeNardo SJ
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3330s-3336s. PubMed ID: 10541382
[TBL] [Abstract][Full Text] [Related]
54. Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A.
Richman CM; DeNardo SJ; O'Donnell RT; Goldstein DS; Shen S; Kukis DL; Kroger LA; Yuan A; Boniface GR; Griffith IJ; DeNardo GL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3243s-3248s. PubMed ID: 10541370
[TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetics and bioactivity of 1,4,7,10-tetra-azacylododecane off',N'',N'''-tetraacetic acid (DOTA)-bismuth-conjugated anti-Tac antibody for alpha-emitter (212Bi) therapy.
Junghans RP; Dobbs D; Brechbiel MW; Mirzadeh S; Raubitschek AA; Gansow OA; Waldmann TA
Cancer Res; 1993 Dec; 53(23):5683-9. PubMed ID: 8242624
[TBL] [Abstract][Full Text] [Related]
56. Blood pharmacokinetics of various monoclonal antibodies labeled with a new trifunctional chelating reagent for simultaneous conjugation with 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid and biotin before radiolabeling.
Wang Z; Mårtensson L; Nilsson R; Bendahl PO; Lindgren L; Ohlsson T; Sjögren HO; Strand SE; Tennvall J
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7171s-7177s. PubMed ID: 16203818
[TBL] [Abstract][Full Text] [Related]
57. Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of yttrium-90.
Nardelli A; Castaldi E; Ortosecco G; Speranza A; Storto G; Pace L; Salvatore M
Appl Radiat Isot; 2011 Jan; 69(1):52-5. PubMed ID: 20869877
[TBL] [Abstract][Full Text] [Related]
58. Trifunctional conjugation reagents. Reagents that contain a biotin and a radiometal chelation moiety for application to extracorporeal affinity adsorption of radiolabeled antibodies.
Wilbur DS; Chyan MK; Hamlin DK; Kegley BB; Nilsson R; Sandberg BE; Brechbiel M
Bioconjug Chem; 2002; 13(5):1079-92. PubMed ID: 12236790
[TBL] [Abstract][Full Text] [Related]
59. Determining maximal tolerable dose of the monoclonal antibody BR96 labeled with 90Y or 177Lu in rats: establishment of a syngeneic tumor model to evaluate means to improve radioimmunotherapy.
Mårtensson L; Wang Z; Nilsson R; Ohlsson T; Senter P; Sjögren HO; Strand SE; Tennvall J
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7104s-7108s. PubMed ID: 16203809
[TBL] [Abstract][Full Text] [Related]
60. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
Wong JY; Shibata S; Williams LE; Kwok CS; Liu A; Chu DZ; Yamauchi DM; Wilczynski S; Ikle DN; Wu AM; Yazaki PJ; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5842-52. PubMed ID: 14676105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]